{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T05:35:39Z","timestamp":1793079339523,"version":"4.5.0"},"reference-count":20,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Taisho Seiyaku Kabushiki Kaisha"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Xenobiotica"],"published-print":{"date-parts":[[2026,11,26]]},"DOI":"10.1080\/00498254.2026.2720767","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:10:53Z","timestamp":1788502253000},"page":"872-881","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["<i>In vitro<\/i>\n                    assessments for pharmacokinetic drug-drug interaction potential of vornorexant, a novel dual orexin 1\/2 receptor antagonist"],"prefix":"10.1080","volume":"56","author":[{"given":"Shunsuke","family":"Kamigaso","sequence":"first","affiliation":[{"name":"Drug Safety and Pharmacokinetics, Pharmaceutical Research Center, Taisho Pharmaceutical Co., Ltd","place":["Saitama, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Konno","sequence":"additional","affiliation":[{"name":"Drug Safety and Pharmacokinetics, Pharmaceutical Research Center, Taisho Pharmaceutical Co., Ltd","place":["Saitama, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiji","family":"Kambe","sequence":"additional","affiliation":[{"name":"Development Planning, Taisho Pharmaceutical Co., Ltd","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hachiuma","sequence":"additional","affiliation":[{"name":"Drug Safety and Pharmacokinetics, Pharmaceutical Research Center, Taisho Pharmaceutical Co., Ltd","place":["Saitama, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Mizuno-Yasuhira","sequence":"additional","affiliation":[{"name":"Drug Safety and Pharmacokinetics, Pharmaceutical Research Center, Taisho Pharmaceutical Co., Ltd","place":["Saitama, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-21-0155"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2015.05.012"},{"key":"e_1_3_4_4_1","unstructured":"Eisai Inc. 2019. DAYVIGOTM (lemborexant) tablets: labeling-package insert. [accessed 3 Mar 2026]. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=212028"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2024-325362"},{"key":"e_1_3_4_6_1","unstructured":"Idorsia Pharmaceuticals US Inc. 2022. QUVIVIQ (daridorexant) tablets: labeling-package insert. [accessed 3 Mar 2026]. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=214985"},{"key":"e_1_3_4_7_1","unstructured":"International Council for the Harmonization of Technical Requirements for Pharmaceuticals for Human Use ICH Harmonized Guideline for Drug Interaction Studies M12 (ICH M12). 2024. [accessed 3 Mar 2026]. https:\/\/database.ich.org\/sites\/default\/files\/ICH_M12_Step4_Guideline_2024_0521_0.pdf"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13930"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1183"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0272-7358(99)00063-x"},{"key":"e_1_3_4_11_1","unstructured":"Merck Sharp & Dohme Corp. 2014. BELSOMRA\u00ae (suvorexant) tablets: labeling-package insert. [accessed 3 Mar 2026]. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=204569"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.7172"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.26929"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2006.06.002"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(00)80949-6"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1755227"},{"issue":"5","key":"e_1_3_4_17_1","first-page":"490","article-title":"Sleep in the Elderly","volume":"117","author":"Tatineny P","year":"2020","unstructured":"Tatineny P, Shafi F, Gohar A, Bhat A. 2020. Sleep in the Elderly. Mo Med. 117(5):490\u2013495. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7723148\/.","journal-title":"Mo Med"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2021.1918361"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-022-06089-6"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaf291"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12261"}],"container-title":["Xenobiotica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/00498254.2026.2720767","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/00498254.2026.2720767","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/00498254.2026.2720767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T05:29:06Z","timestamp":1793078946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/00498254.2026.2720767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,11,26]]}},"alternative-id":["10.1080\/00498254.2026.2720767"],"URL":"https:\/\/doi.org\/10.1080\/00498254.2026.2720767","relation":{},"ISSN":["0049-8254","1366-5928"],"issn-type":[{"value":"0049-8254","type":"print"},{"value":"1366-5928","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ixen20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ixen20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}